Therapeutic indication GlucaGen is indicated for treatment of severe hypoglycaemic reactions, which may occur in the management of insulin treated children and adults with diabetes mellitus. Diagnostic indication GlucaGen is indicated for motility inhibition in examinations of the gastrointestinal tract in adults.
Xeris Pharmaceuticals announced that the European Commission (EC) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Xeris Pharmaceuticals announced positive findings from a global Phase III trial of the Gvoke HypoPen, its ready-to-use (RTU) room-temperature stable...
Zealand Pharma announced it has achieved primary and key secondary endpoints in the pivotal Phase III trial with ZP 4207...
Zealand Pharma announced that the primary and key secondary objectives of the first multinational Phase III clinical trial of ZP...
Zealand Pharma A/S presented elaborated results from two Phase III clinical studies with dasiglucagon as treatment for severe hypoglycemia as well as one preclinical PK/PD study investigating aqueous versus DMSO formulations of glucagon and the pharmacodynamics of dasiglucagon in aqueous solution at the 80th Scientific Sessions of the American Diabetes Association (ADA) held as a virtual meeting June 12-16, 2020.